 |
|
What Is Deep Brain Stimulation "Failure" and How Do We Manage Our Own Failures?—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We appreciate the insightful comments of Dr Hariz, 1 of the leaders in the field of stereotactic neurosurgery and a scrupulous observer of surgical outcomes and adverse effects. Additional information may further clarify our recent article on referred "DBS failures" in the ARCHIVES.1 Undoubtedly, the most important issue raised by Dr Hariz is what constitutes an unsatisfactory result. These criteria are difficult to strictly define, in part because of the syndromic nature of Parkinson disease. In fact, while objective success of DBS therapy has been classically measured in terms of Unified Parkinson’s Disease Rating Scale improvement and levodopa-equivalent reduction, the disabling role of Parkinson disease goes beyond motor impairment and medication adverse effects. This impairment includes features that are not considered a therapeutic target of DBS (eg, depression, sleep disturbance, dysarthria, autonomic dysfunction, and sensory symptoms). Paradoxically, a successful motor outcome could in some cases unmask . . . [Full Text of this Article] AUTHOR INFORMATION
Michele Tagliati, MD;
Ron Alterman, MD;
Michael S. Okun, MD;
Hubert H. Fernandez, MD;
Ramon L. Rodriguez, MD;
Kelly D. Foote, MD;
Michael Pourfar, MD;
Sharon Metz;
Ruth Hagestuen
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED ARTICLES
What Is Deep Brain Stimulation "Failure" and How Do We Manage Our Own Failures?
Marwan I. Hariz
Arch Neurol. 2005;62(12):1938.
EXTRACT
| FULL TEXT
Management of Referred Deep Brain Stimulation Failures: A Retrospective Analysis From 2 Movement Disorders Centers
Michael S. Okun, Michele Tagliati, Michael Pourfar, Hubert H. Fernandez, Ramon L. Rodriguez, Ron L. Alterman, and Kelly D. Foote
Arch Neurol. 2005;62(8):1250-1255.
ABSTRACT
| FULL TEXT
|
